Navigation Links
Prix Galien USA Announces 2009 Final Candidates
Date:8/7/2009

Honorees for Best Pharmaceutical Agent, Best Biotechnology Product and Best Medical Technology to be recognized at Sept. 30 gala ceremony

NEW YORK, Aug. 7 /PRNewswire-USNewswire/ -- The 2009 Prix Galien USA will recognize innovative biopharmaceutical drugs and medical technologies that have made a deep impact on the quality of human life at a gala event on September 30. Candidates for the 2009 program provide relief to millions of people living with chronic diseases including cardiovascular disease and diabetes and treatments for people living with cancer and HIV/AIDS. The 2009 Prix Galien USA ceremony will again be emceed by Charlie Rose at the American Museum of Natural History in New York.

Final candidates for the Prix Galien USA 2009 awards are:

Best Pharmaceutical Agent:

  • AstraZeneca, CRESTOR(R)
  • Celgene, Vidaza(R)
  • Novartis Oncology, GLEEVEC(R)
  • Novartis Pharmaceuticals, EXELON(R)( )PATCH
  • Pfizer, Zyvox(R)
  • Schering-Plough, TEMODAR(R) and ZETIA(R)
  • Teva Neurosciences, AZILECT(R)
  • Wyeth, TORISEL(R)

Best Biotechnology Product:

  • Amgen, Nplate(R)
  • GlaxoSmithKline, PROMACTA(R) and Tykerb(R)
  • Schering-Plough, PEGINTRON(R)
  • Tibotec, INTELENCE(TM)
  • United Therapeutics, REMODULIN(R)
  • Wyeth, Prevnar (R)

Best Medical Device:

  • Abbott Vascular, XIENCE (R)
  • Boston Scientific, TAXUS (R)
  • DCA Design, Lantus(R)( )SoloSTAR(R)
  • GlaxoSmithKline, Veramyst(R)( )Mistpro(TM)
  • Veridex, CellSearch(R) CTC Test

"Nominees for the Prix Galien USA stand apart from other drugs and technologies in the marketplace for the amount of research and level of skill that was invested in the development of these products that improve lives," said Gerald Weissmann, M.D., Prix Galien USA committee chair, New York University professor emeritus and editor-in-chief of The FASEB Journal.

Prix Galien USA honorees are judged on the basis of the innovative nature of the development, application or clinical utility of the drug or technology and whether its discovery can be applied to future biomedical science.

In 2008, the Prix Galien USA committee recognized Selzentry(TM)( )(Pfizer Inc.), Isentress(R) (Merck & Co., Inc.), Soliris(R) (Alexion Pharmaceuticals, Inc.), INFUSE(R) (Wyeth) and Revlimid(R)( )(The Celgene Corporation).

The Prix Galien USA award is considered the industry's highest accolade for pharmaceutical research and development -- equivalent to the Nobel Prize. The award committee comprises 11 individuals including seven Nobel Laureates, founders of major biotech companies and editors of world-renowned biology journals. For details about the Prix Galien USA award and committee visit www.prix-galien-usa.com.


'/>"/>
SOURCE Prix Galien USA
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Prix Galien USA Announces 2008 Final Candidates
2. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
3. Alexions Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product
4. 2009 Prix Galien USA Now Accepting Nominations for Top Prize in Biopharmaceutical Research and Development
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... -- Novan, Inc. today announced that Director Robert A. Ingram ... Novan. In addition, Robert Keegan has been appointed to ... . --> North Carolina . ... total of $32.8 million of net proceeds in a private Mezzanine ... throughout the Research Triangle area of North Carolina ...
(Date:2/8/2016)... ... ... Information Management Services ( IMS ) is pleased to announce a major ... foundation and is so significant it was endowed with a new name, BSI Engage. ... results, a streamlined layout and a more intuitive format for navigating the system. ...
(Date:2/8/2016)... (NYSE MKT: NNVC) (the "Company"), a nanomedicine company developing anti-viral drugs, ... present information about the company,s programs at the BIOCEO conference today ... City . --> --> ... Registered attendees can request a one on one meeting through the conference ... --> New York City . --> ...
(Date:2/8/2016)... 8, 2016 --> ... the "Company"), the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today ... Chlamydia trachomatis (CT) test to be launched on the Company,s ... (98/79/EC), the CT test is now cleared for sale within ... The launch of the io® CT test signals a ...
Breaking Biology Technology:
(Date:1/21/2016)... , January 21, 2016 ... a new market research report "Emotion Detection and Recognition ... Software Tools (Facial Expression, Voice Recognition and Others), ... Global forecast to 2020", published by MarketsandMarkets, the ... to reach USD 22.65 Billion by 2020, at ...
(Date:1/20/2016)... 2016   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce the attainment of ... the result of the company,s laser focus on (and ... , it,s comprehensive, easy-to-use and highly affordable cloud-based technology ... Key MedNet growth achievements in 2015 include: ...
(Date:1/18/2016)... 2016  Extenua Inc., a pioneering developer of ... and access of ubiquitous on-premise and cloud storage, today ... Cyber.  ... C4ISR and Cyber initiatives in support of National ... technology solutions," said Steve Visconti , Extenua ...
Breaking Biology News(10 mins):